Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes (Q35043106)

6 August 2017

1 reference

title

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes (English)

1 reference

6 August 2017

1 reference

Terry W Hermiston

1

1 reference

PubMed ID

12522441

6 August 2017

Irene Kuhn

series ordinal

2

1 reference

6 August 2017

1 December 2002

1 reference

6 August 2017

1 reference

6 August 2017

9

1 reference

6 August 2017

1022-1035

1 reference

6 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700542

6 August 2017

0 references

cites work

Oncolytic viruses as therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Cytolytic viruses as potential anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Studies on the use of viruses in the treatment of carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

The emerging fields of suicide gene therapy and virotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Cancer gene therapy: fringe or cutting edge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Viral-mediated gene transfer for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

The promise and obstacle of p53 as a cancer therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Induction of the growth inhibitor IGF-binding protein 3 by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Tumor necrosis factor as an antineoplastic agent: pitfalls and promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Influence of the bystander effect on HSV-tk/GCV gene therapy. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Vascular attack as a therapeutic strategy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Current status of antiangiogenic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Progress in antiangiogenic gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Gene therapy for antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Tumor regression by targeted gene delivery to the neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

The dendritic cell system and its role in immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Identifying strategies for immune intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and t

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Fas ligand mediates activation-induced cell death in human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Tumour escape from immune surveillance through dendritic cell inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Tumor immunology: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

On the role of costimulation in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Impediments to successful immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Tumor immunology--towards a paradigm of reciprocal research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Spinning molecular immunology into successful immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Tumor-induced immune dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Phosphatidylinositol 3-kinases in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Phosphoinositide 3-kinase inhibition in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Oncolytic biotherapy: a novel therapeutic plafform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Intravascular injections of a conditional replicative adenovirus (adl118) prevent metastatic disease in human breast carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Reovirus oncolysis of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Systemic therapy of myeloma xenografts by an attenuated measles virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

1 reference

7 January 2021

The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

Therapeutic angiogenesis in ischemic limbs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

Dendritic cell development and maturation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

Immunotherapy of metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

Tumor immunology: the glass is half full

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

Transcriptional targeting of herpes simplex virus for cell-specific replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700542

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700542

1 reference

6 August 2017

1 reference

PubMed ID

12522441